Defunct Company
Total Trials
17
As Lead Sponsor
15
As Collaborator
2
Total Enrollment
176,392
NCT01221831
Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2010
Completion: Sep 30, 2011
NCT02852681
Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers
Phase: Phase 1
Start: Aug 31, 2015
Completion: Apr 30, 2016
NCT02720224
Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol
Start: Feb 29, 2016
NCT02874248
E4/DRSP Single and Multiple Dose PK and Early QT Study
Start: May 31, 2016
Completion: Nov 21, 2016
NCT02817828
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study
Phase: Phase 3
Start: Jun 30, 2016
Completion: Apr 26, 2018
NCT02817841
E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study
Start: Aug 30, 2016
Completion: Nov 16, 2018
NCT02957630
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
Phase: Phase 1/2
Start: Sep 30, 2016
Completion: Oct 9, 2017
NCT03075956
Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers
Start: Jan 31, 2017
Completion: Aug 2, 2017
NCT03091595
E4/DRSP Ovarian Function Inhibition Study
Start: Feb 7, 2017
Completion: Jun 8, 2018
NCT03512860
Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study
Start: Apr 12, 2018
Completion: Oct 8, 2018
NCT04090957
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
Start: Sep 27, 2019
Completion: Aug 18, 2022
NCT04209543
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
Start: Dec 30, 2019
Completion: Feb 8, 2024
NCT04792385
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
Start: Dec 28, 2020
Completion: Nov 24, 2023
NCT04819906
Effect of Estetrol Monohydrate (E4) on QTc Interval
Start: Mar 9, 2021
Completion: Jul 14, 2021
NCT06028555
International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study
Phase: N/A
Role: Collaborator
Start: Jun 28, 2023
Completion: Oct 31, 2028
NCT06308614
Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
Start: Jan 29, 2024
Completion: Apr 21, 2025
NCT06186271
International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
Start: Apr 24, 2025
Completion: Jun 30, 2029